November 2007
by Joseph Peuskens, Jitendra Trivedi, Sergiy Malyarov, Martin Brecher, Ola Svensson, Frank Miller, Inger Persson, and Didier Meulien on behalf of the Study D1444C00004 investigators
Dr. Peuskens is with Universitair Psychiatrisch Centrum KU Leuven, Campus St Jozef Kortenberg, Belgium; Dr. Trivedi is with King George Medical University, Lucknow, India; Dr. Malyarov is with Kyiv Psychoneurological Hospital, Kyiv, Ukraine; Dr. Brecher is with AstraZeneca Pharmaceuticals, Wilmington, Delaware, US; and Drs. Svensson, Miller, Persson, and Meulien are with AstraZeneca Research and Development in Södertälje, Sweden.
This is protected content.
Popularity: unranked [?]
Related posts
- Pancreatitis and Diabetic Ketoacidosis with Quetiapine Use
- Is Seroquel Developing an Illicit Reputation for Misuse/Abuse?
- Real-world Data on Atypical Antipsychotic Medication Side Effects
- The 4-Item Negative Symptom Assessment (NSA-4) Instrument: A Simple Tool for Evaluating Negative Symptoms in Schizophrenia Following Brief Training
- When Does Cognitive Decline Occur in the Period Prior to the First Episode of Schizophrenia?
- COGNITION AND SCHIZOPHRENIA: Is There a Role for Cognitive Assessments in Diagnosis and Treatment?
- Risperidone Long-Acting Injections: Successful Alternative Deltoid Muscle Injections for Refractory Schizophrenia
- Katatonia: A New Conceptual Understanding of Catatonia and a New Rating Scale
- Direct Measurement of Disability
- Social Cognition: The Key Factor Predicting Social Outcome in People with Schizophrenia?
Posted in Original Research | No Comments »
